High Fat Diet for Cardiac Metabolic Reprogramming

NCT ID: NCT06747429

Last Updated: 2024-12-24

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-31
• Study Completion Date: 2026-07-31

Brief Summary

The heart is a unique organ that performs an incessant work to pump blood throughout the body. For this massive effort, it requires a very high supply of energy. Mitochondria are small components of the cells responsible for the production of energy. To produce energy, mitochondria from cardiac cells can use fuel of different origins (fats, glucose, proteins, etc). In normal circumstances, cardiac mitochondria use preferentially fats since they are more efficient in terms of quantify of energy produced. Recent data from our consortium has demonstrated that if the cardiac mitochondria switch the primary source of fuel (from fats to glucose), this results in a poor performance of the organ, which cannot supply the whole body with enough blood. This is known as heart failure. In experimental models of heart failure, we have demonstrated that a high fat diet is able to reverse the metabolic switch and make the cardiac cells mitochondria use again fats as the primary substrate to produce energy. This translates into a recovery of heart failure. In the present project, we plan to bring this concept to the human setting and perform a pilot clinical study where patients with heart failure are put in a dietary program consisting of high fat diet. The effect of this nutritional approach will be evaluated by state-of-the-art non-invasive imaging technology.

Detailed Description

Heart failure (HF) is a progressive condition in which the heart muscle is unable to pump blood effectively to meet the body's needs. It affects millions of people globally and imposes a significant burden on healthcare systems due to its high morbidity, mortality, and economic costs. As the prevalence of HF continues to rise, exploring targeted and innovative treatment strategies is becoming increasingly important.

The heart sustains high energy demands and primarily relies on fatty acids as its energy source in the fasting state, with a smaller contribution from glucose. During the progression of HF, there is a shift in cardiac substrate preference toward increased glucose reliance and reduced fatty acid utilization. Initially considered a protective adaptation against oxygen deficiency and lipotoxicity, this metabolic shift led to suggestions that inhibiting fatty acid oxidation could be a therapeutic strategy for HF. However, more recent evidence indicates that enhancing fatty acid utilization through a high-fat diet may attenuate cardiac dysfunction.

Animal studies have demonstrated that increasing fatty acid utilization can reverse myocardial metabolic alterations and improve cardiac function in models of progressive dilated cardiomyopathy (DCM) with reduced ejection fraction. In one study, the administration of a high-fat diet restored normal myocardial metabolism, resulting in disease regression. Similarly, research using large animal models has shown that high-fat diets can significantly improve left ventricular ejection fraction (LVEF), further supporting the potential benefits of this approach.

In human studies, preliminary findings suggest that lipid-based interventions may acutely improve cardiac function in individuals with HF and reduced LVEF. However, evidence on the long-term efficacy and safety of high-fat dietary patterns in HF management remains limited.

This study aims to compare the effects of a high-fat diet versus a standard diet with a conventional macronutrient composition on non-ischemic DCM with reduced LVEF. The primary objective is to evaluate and compare the impact of a high-fat diet versus a standard diet on LVEF. Secondary objectives include assessing the effects on left ventricular strain, diastolic function, and blood parameters, as well as evaluating the feasibility and degree of adherence to each dietary intervention.

Conditions

Hearth Failure Secondary to Non-ischemic DCM with Reduced LVEF (≤40%)

Keywords

heart failure; dilated cardiomyopathy; high-fat diet; clinical trial

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: SINGLE

Study Groups

High fat diet

Patients receiving a high-fat diet

Group Type: EXPERIMENTAL

High fat diet

Intervention Type: OTHER

Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 70% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and the remaining calories from carbohydrates (10-20%).

Control

Patients receiving a standard diet

Group Type: ACTIVE_COMPARATOR

Standard diet

Intervention Type: OTHER

Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 30% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and 50-60% from carbohydrates.

Interventions

High fat diet

Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 70% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and the remaining calories from carbohydrates (10-20%).

Intervention Type: OTHER

Standard diet

Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 30% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and 50-60% from carbohydrates.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• diagnosis with HF secondary to non-ischemic DCM with reduced LVEF (≤40%)
• 18 years or older
• informed consent provided

Exclusion Criteria

• diagnosis of ischemic dilated cardiomyopathy
• recent changes in drug treatment
• significant HF impairment within the past year
• uncontrolled dyslipidemia
• claustrophobia
• presence of a pacemaker or implantable cardiac defibrillator (ICD)
• liver diseases
• life expectancy less than 12 months
• baseline fat intake exceeding 40% of total daily energy intake

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

INSTITUTO DE SALUD CARLOS III (ISCIII)

UNKNOWN

Sponsor Role: collaborator

Puerta de Hierro Majadahonda University Hospital

UNKNOWN

Sponsor Role: collaborator

Nicole Karam, European Hospital Georges Pompidou, Paris, France

UNKNOWN

Sponsor Role: collaborator

Carol Davila University of Medicine and Pharmacy Bucharest

UNKNOWN

Sponsor Role: collaborator

Azienda Ospedaliero-Universitaria Careggi

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Francesco Sofi, Phd, MD

Role: CONTACT

Phone: +39 0557946519

Email: francesco.sofi@unifi.it

References

Watson WD, Green PG, Lewis AJM, Arvidsson P, De Maria GL, Arheden H, Heiberg E, Clarke WT, Rodgers CT, Valkovic L, Neubauer S, Herring N, Rider OJ. Retained Metabolic Flexibility of the Failing Human Heart. Circulation. 2023 Jul 11;148(2):109-123. doi: 10.1161/CIRCULATIONAHA.122.062166. Epub 2023 May 18.

Reference Type: BACKGROUND

PMID: 37199155 (View on PubMed)

Stanley WC, Dabkowski ER, Ribeiro RF Jr, O'Connell KA. Dietary fat and heart failure: moving from lipotoxicity to lipoprotection. Circ Res. 2012 Mar 2;110(5):764-76. doi: 10.1161/CIRCRESAHA.111.253104.

Reference Type: BACKGROUND

PMID: 22383711 (View on PubMed)

Stanley WC, Recchia FA. Lipotoxicity and the development of heart failure: moving from mouse to man. Cell Metab. 2010 Dec 1;12(6):555-6. doi: 10.1016/j.cmet.2010.11.016.

Reference Type: BACKGROUND

PMID: 21109186 (View on PubMed)

Martinez-Milla J, Galan-Arriola C, Carnero M, Cobiella J, Perez-Camargo D, Bautista-Hernandez V, Rigol M, Solanes N, Villena-Gutierrez R, Lobo M, Mateo J, Vilchez-Tschischke JP, Salinas B, Cusso L, Lopez GJ, Fuster V, Desco M, Sanchez-Gonzalez J, Ibanez B. Translational large animal model of hibernating myocardium: characterization by serial multimodal imaging. Basic Res Cardiol. 2020 Apr 14;115(3):33. doi: 10.1007/s00395-020-0788-0.

Reference Type: BACKGROUND

PMID: 32291522 (View on PubMed)

Wai T, Garcia-Prieto J, Baker MJ, Merkwirth C, Benit P, Rustin P, Ruperez FJ, Barbas C, Ibanez B, Langer T. Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science. 2015 Dec 4;350(6265):aad0116. doi: 10.1126/science.aad0116.

Reference Type: BACKGROUND

PMID: 26785494 (View on PubMed)

Tan Y, Li M, Wu G, Lou J, Feng M, Xu J, Zhou J, Zhang P, Yang H, Dong L, Li J, Zhang X, Gao F. Short-term but not long-term high fat diet feeding protects against pressure overload-induced heart failure through activation of mitophagy. Life Sci. 2021 May 1;272:119242. doi: 10.1016/j.lfs.2021.119242. Epub 2021 Feb 16.

Reference Type: BACKGROUND

PMID: 33607155 (View on PubMed)

Guo Y, Wang Z, Qin X, Xu J, Hou Z, Yang H, Mao X, Xing W, Li X, Zhang X, Gao F. Enhancing fatty acid utilization ameliorates mitochondrial fragmentation and cardiac dysfunction via rebalancing optic atrophy 1 processing in the failing heart. Cardiovasc Res. 2018 Jun 1;114(7):979-991. doi: 10.1093/cvr/cvy052.

Reference Type: BACKGROUND

PMID: 29490017 (View on PubMed)

Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC. Low-carbohydrate/high-fat diet attenuates pressure overload-induced ventricular remodeling and dysfunction. J Card Fail. 2008 May;14(4):327-35. doi: 10.1016/j.cardfail.2007.11.003.

Reference Type: BACKGROUND

PMID: 18474346 (View on PubMed)

Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol. 2014 Apr;171(8):2080-90. doi: 10.1111/bph.12475.

Reference Type: BACKGROUND

PMID: 24147975 (View on PubMed)

Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007 Mar 15;356(11):1140-51. doi: 10.1056/NEJMra063052. No abstract available.

Reference Type: BACKGROUND

PMID: 17360992 (View on PubMed)

Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013 Aug 30;113(6):709-24. doi: 10.1161/CIRCRESAHA.113.300376.

Reference Type: BACKGROUND

PMID: 23989714 (View on PubMed)

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available.

Reference Type: BACKGROUND

PMID: 34447992 (View on PubMed)

Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. doi: 10.1093/cvr/cvac013.

Reference Type: BACKGROUND

PMID: 35150240 (View on PubMed)

Other Identifiers

101095426

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

CARDINNOV

Identifier Type: -

Identifier Source: org_study_id